1. Home
  2. CINGW vs CLMT Comparison

CINGW vs CLMT Comparison

Compare CINGW & CLMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • CLMT
  • Stock Information
  • Founded
  • CINGW N/A
  • CLMT 1916
  • Country
  • CINGW United States
  • CLMT United States
  • Employees
  • CINGW 13
  • CLMT N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • CLMT Oil & Gas Production
  • Sector
  • CINGW Health Care
  • CLMT Energy
  • Exchange
  • CINGW Nasdaq
  • CLMT Nasdaq
  • Market Cap
  • CINGW N/A
  • CLMT N/A
  • IPO Year
  • CINGW 2021
  • CLMT 2006
  • Fundamental
  • Price
  • CINGW $0.05
  • CLMT $18.93
  • Analyst Decision
  • CINGW
  • CLMT Strong Buy
  • Analyst Count
  • CINGW 0
  • CLMT 4
  • Target Price
  • CINGW N/A
  • CLMT $25.75
  • AVG Volume (30 Days)
  • CINGW N/A
  • CLMT 989.5K
  • Earning Date
  • CINGW N/A
  • CLMT 02-21-2025
  • Dividend Yield
  • CINGW N/A
  • CLMT N/A
  • EPS Growth
  • CINGW N/A
  • CLMT N/A
  • EPS
  • CINGW N/A
  • CLMT N/A
  • Revenue
  • CINGW N/A
  • CLMT $4,216,399,999.00
  • Revenue This Year
  • CINGW N/A
  • CLMT N/A
  • Revenue Next Year
  • CINGW N/A
  • CLMT N/A
  • P/E Ratio
  • CINGW N/A
  • CLMT N/A
  • Revenue Growth
  • CINGW N/A
  • CLMT 0.30
  • 52 Week Low
  • CINGW N/A
  • CLMT $9.97
  • 52 Week High
  • CINGW N/A
  • CLMT $25.29
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • CLMT 37.57
  • Support Level
  • CINGW N/A
  • CLMT $20.61
  • Resistance Level
  • CINGW N/A
  • CLMT $23.20
  • Average True Range (ATR)
  • CINGW 0.00
  • CLMT 1.34
  • MACD
  • CINGW 0.00
  • CLMT -0.26
  • Stochastic Oscillator
  • CINGW 0.00
  • CLMT 1.63

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: